Skip to content
10-K

Annual Report

OnKure Therapeutics, Inc. OKUR

0000950170-25-036252

← back to feed
Filed
Mar 10, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Revenue FY 2024 · Dec 31, 2024 $0
Shares Diluted restated FY 2024 · Dec 31, 2023 283.82K sh
Capex restated FY 2024 · Dec 31, 2023 $246K
Operating Cash Flow restated FY 2024 · Dec 31, 2023 −$34.55M
Cash And Equivalents restated FY 2024 · Dec 31, 2023 $29.88M
Current Liabilities restated FY 2024 · Dec 31, 2023 $7.29M
Total Liabilities restated FY 2024 · Dec 31, 2023 $7.75M
Current Assets restated FY 2024 · Dec 31, 2023 $33.77M
Total Assets restated FY 2024 · Dec 31, 2023 $35.73M
Eps Diluted restated FY 2024 · Dec 31, 2023 −$124.41
Eps Basic restated FY 2024 · Dec 31, 2023 −$124.41
Sga Expense restated FY 2024 · Dec 31, 2023 $4.82M
Rd Expense restated FY 2024 · Dec 31, 2023 $32.12M
Net Income restated FY 2024 · Dec 31, 2023 −$35.31M
Operating Income restated FY 2024 · Dec 31, 2023 −$36.93M
Stockholders Equity restated FY 2024 · Dec 31, 2022 −$54.42M